黄洁玉 张 敏暨南大学医学院附属广州市红十字会医院呼吸内科，广东广州 510220

    蛋白酶体抑制剂在肺癌治疗中的研究进展

    黄洁玉张敏

    暨南大学医学院附属广州市红十字会医院呼吸内科，广东广州510220

    泛素-蛋白酶体通路(UPP)是细胞内重要的蛋白质降解系统。研究表明UPP参与恶性肿瘤多种细胞生物学过程的调节，影响其发生、发展。蛋白酶体抑制剂通过阻断UPP，可抑制肿瘤细胞生长，成为肿瘤治疗的新方法。肺癌在人类癌症死亡原因中居于首位，蛋白酶体抑制剂对肺癌的疗效研究仍在进行，其作用机制复杂，与NF-κB的下调、细胞周期调控、PTEN/PI3K/Akt通路和P53的调节等有关。本文对蛋白酶体抑制剂在肺癌治疗的新进展进行综述。

    蛋白酶体抑制剂；泛素-蛋白酶体通路；肺癌；作用机制

    [Abstract]The ubiquitin-proteasome pathway is the principle pathway for intracellular protein degradation.Research shows that ubiquitin-proteasome pathway plays a significant role in the genesis and progression of malignancy by regulating many processes of cellular biology.Proteasome inhibitors targeting the ubiquitin-proteasome pathway can inhibit tumorous cellular growth，becoming a novel class of potent and effective antitumor agents.Lung cancer is the leading cause of cancer-related deaths globally.The study about the effect of proteasome inhibitors on lung cancer is ongoing.The mechanisms are complicated，relating to the down-regulation of NF-κB，cell cycle control，PTEN/PI3K/ AKT pathway，the regulation of P53 and others.The recent advances about proteasome inhibitors in the treatment of lung cancer is going to be reviewed in this paper. ......